We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+50.06%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$178M
AUM Growth
-$83.5M
Cap. Flow
-$139M
Cap. Flow %
-77.69%
Top 10 Hldgs %
100%
Holding
14
New
–
Increased
1
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$1.69M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$45.1M
2
BPMC
Blueprint Medicines
BPMC
+$41.1M
3
ASND icon
Ascendis Pharma A/S
ASND
+$21.1M
4
AIMT
Aimmune Therapeutics
AIMT
+$12.8M
5
EPZM
Epizyme, Inc
EPZM
+$4.61M

Sector Composition

Rank Sector Weight
1 Healthcare 47.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$56.8M 31.84%
2,350,477
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$37M 20.75%
1,750,000
-206,362
-11% -$3.64M
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.8M 13.34%
326,482
+27,816
+9% +$1.69M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$16.9M 9.48%
687,427
-310,851
-31% -$4.61M
BOLD
5
DELISTED
Audentes Therapeutics, Inc
BOLD
$13.9M 7.82%
233,067
-82,264
-26% -$3.09M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$13.5M 7.57%
254,923
– –
NTRA icon
7
Natera
NTRA
$36.3B
$7.03M 3.94%
208,768
-77,700
-27% -$2.86M
REPL icon
8
Replimune Group
REPL
$434M
$4.5M 2.52%
313,922
-255,740
-45% -$3.69M
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$2.95M 1.65%
1,504,710
-3,381
-0.2% -$12.7K
ASND icon
10
Ascendis Pharma A/S
ASND
$16.4B
$1.94M 1.09%
13,922
-190,166
-93% -$21.1M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
– –
-559,381
Closed -$41.1M
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
– –
-611,893
Closed -$12.8M
ALDR
13
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-2,393,612
Closed -$45.1M
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-53,345
Closed -$2.23M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2019 Portfolio in Review

As of Q4 2019, Foresite Capital Management III held 14 positions worth $178M, down 32% from $262M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III withdrew a net $139M in Q4 2019, closing 4 positions and reducing 7 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $45.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 68% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $1.69M to MyoKardia, Inc. Common Stock.

  • Foresite Capital Management III added most to MyoKardia, Inc. Common Stock in Q4 2019, an estimated $1.69M increase.
  • Foresite Capital Management III's biggest Q4 2019 reduction was Ascendis Pharma A/S, cutting an estimated $21.1M.
  • Foresite Capital Management III fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $45.1M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $178M portfolio in Q4 2019.
  • Foresite Capital Management III opened 0 new positions and closed 4 in Q4 2019.
  • Foresite Capital Management III's portfolio value fell 32% quarter-over-quarter to $178M.

Based on Foresite Capital Management III's 13F filing for Q4 2019, filed 14 Feb 2020.